Overview

This trial is active, not recruiting.

Conditions extensive stage small cell lung cancer, recurrent small cell lung cancer
Treatments cixutumumab, vismodegib, cisplatin, etoposide, laboratory biomarker analysis
Phase phase 2
Target PTCH1
Sponsor National Cancer Institute (NCI)
Start date July 2009
End date September 2014
Trial size 169 participants
Trial identifier NCT00887159, CDR0000640898, E1508, ECOG-E1508, NCI-2011-01917, U10CA021115, U10CA180820

Summary

This randomized phase II trial studies cisplatin and etoposide to see how well they work when given with or without vismodegib or cixutumumab in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Etoposide may slow the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vismodegib may slow the growth of tumor cells. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving cisplatin and etoposide are more effective when given together with vismodegib or cixutumumab in treating small cell lung cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
cisplatin CACP
Given IV
etoposide EPEG
Given IV
laboratory biomarker analysis
Correlative studies
(Experimental)
Patients receive cisplatin and etoposide as in Arm I and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
vismodegib Erivedge
Given PO
cisplatin CACP
Given IV
etoposide EPEG
Given IV
laboratory biomarker analysis
Correlative studies
(Experimental)
Patients receive cisplatin and etoposide as in Arm I and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
cixutumumab anti-IGF-1R recombinant monoclonal antibody IMC-A12
Given IV
cisplatin CACP
Given IV
etoposide EPEG
Given IV
laboratory biomarker analysis
Correlative studies

Primary Outcomes

Measure
Progression-free survival
time frame: Time from randomization to death or disease progression, whichever occurs first, assessed up to 3 years

Secondary Outcomes

Measure
Overall survival
time frame: From randomization to death or last known follow-up, assessed up to 3 years
Overall response
time frame: Up to 3 years
Toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
time frame: Up to 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients must have histologically or cytologically confirmed small cell lung cancer - Patients must have extensive stage SCLC - Patients must have measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Absolute neutrophil count (ANC) >= 1,500/mm^3 - Platelets >= 100,000/mm^3 - Total bilirubin =< 1.5 x upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) =< 3 X institutional upper limit of normal (ULN) (=< 5 X ULN if liver function test [LFT] elevations are due to liver metastases) - Creatinine =< 1.5 X institutional upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 x institutional upper limit of normal (ULN) - Leukocytes >= 3,000/mm^3 - Hemoglobin >= 9 g/dL - Fasting serum glucose < 120 mg/dL or below institutional upper limit of normal =< 7 days prior to protocol randomization - Patients with central nervous system (CNS) metastases will be eligible if they have completed a course of CNS radiotherapy and have stable neurologic function for a minimum of 28 days prior to study randomization; radiotherapy must have been completed a minimum of 28 days prior to randomization, and patients must have recovered from any adverse events related to the radiotherapy (except alopecia and grade 1 neuropathy) and have stable neurologic function for a minimum of 28 days prior to study randomization - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation - Women of childbearing potential (WCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse; the two methods of reliable contraception must include one highly effective method (i.e., intrauterine device [IUD], hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e., latex condom, diaphragm, cervical cap); WCBP must be referred to a qualified provider of contraceptive methods if needed - NOTE: The WCBP randomized to Arm B must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following two additional time periods related to this study: 1) while participating in the study; and 2) for at least 12 months after discontinuation from the study - Before starting the study drugs, all WCBP must have a negative pregnancy test (sensitivity of at least 50 mIU/mL); the pregnancy test must be performed within 10-14 days prior to randomization - NOTE: The WCBP randomized to Arm B must have a second pregnancy test performed within the 24 hours prior to the start of the GDC-0449; the subject may not receive GDC-0449 until the investigator has verified that the results of these pregnancy tests are negative - The WCBP randomized to Arm B will be warned that sharing the study drug is prohibited and will be counseled about pregnancy precautions and potential risks or fetal exposure; she must also agree to abstain from donating blood during study participation and at least 12 months after discontinuation from the study drug - NOTE: Male subjects randomized to Arm B must agree to use a latex condom during sexual contact with women of childbearing potential while participating in the study and for at least 12 months following discontinuation from the study even if he has undergone a successful vasectomy - Male subjects randomized to Arm B will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure; male subjects must agree to abstain from donating blood, semen, or sperm during study participation and for at least 3 months after discontinuation from the study drug - Women must not be pregnant or breastfeeding; all females of childbearing potential must have a blood test within 10-14 days prior to randomization to rule out pregnancy - Patients cannot have had prior chemotherapy or biologic therapy for SCLC; patients with prior radiation may be eligible or after palliative radiotherapy for other sites of disease; patients receiving prior radiation cannot start therapy within 14 days after completion of radiation, and must have recovered from adverse events attributed to radiation; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression - Patients may not be receiving any other investigational agents - Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biological composition to GDC-0449 and IMC-A12 or other agents used in the study - Patients must NOT have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible - Patient must not have poorly controlled diabetes mellitus; patients with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting < 120 mg/dL or below institutional upper limit of normal) and that they are on a stable dietary or therapeutic regimen for this condition - Patients who have had major surgery, hormonal therapy (other than replacement), within 4 weeks prior to entering the study or those who have not recovered from adverse events are not eligible - The patient must not have a history of treatment with other agents targeting the IGFR or the Hedgehog signaling pathway

Additional Information

Official title A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Principal investigator Chandra Belani
Description PRIMARY OBJECTIVES: I. To evaluate the progression-free survival of patients with extensive stage small cell lung cancer (SCLC-ED) treated with cisplatin and etoposide (CE), CE with hedgehog (HH) inhibitor GDC-0449 (vismodegib), and CE with Insulin-like Growth Factor-I Receptor (IGF-1R) Monoclonal Antibody (IMC-A12) (cixutumumab). SECONDARY OBJECTIVES: I. To evaluate response rate, overall survival, and toxicity of patients with SCLC-ED treated with CE, CE with GDC-0449, and CE with IMC-A12. II. To explore putative correlates of clinical benefit from combination therapy in tumor and circulating tumor cells in patients treated on this protocol. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM I: Patients receive cisplatin intravenously (IV) over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive cisplatin and etoposide as in Arm I and vismodegib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity. ARM III: Patients receive cisplatin and etoposide as in Arm I and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.
Trial information was received from ClinicalTrials.gov and was last updated in October 2014.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).